Oncomatryx Biopharma S.l.
Clinical trials sponsored by Oncomatryx Biopharma S.l., explained in plain language.
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called OMTX705, which targets a protein found on cancer cells, either alone or combined with immunotherapy drugs (pembrolizumab or tislelizumab). The study involves 150 adults with advanced solid tumors who have no standard treatment o…
Phase: PHASE1 • Sponsor: Oncomatryx Biopharma S.L. • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
New hope for pancreatic cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis early-stage trial tests a new targeted drug (OMTX705) combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study has two parts: first, finding the safest dose of OMTX705, then comparing the new combo against…
Phase: PHASE1 • Sponsor: Oncomatryx Biopharma S.L. • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC